UK-based researchers say they are developing a vaccine aimed at the rare Ebola virus species known as Bundibugyo, which is associated with the current outbreak in the Democratic Republic of the Congo (DRC). Across the reports, the virus is described as killing roughly a third of people infected, with one outlet citing an estimated range of about 30 to 50%. None of the sources report a proven vaccine for Bundibugyo as of now, and the work is presented as new and still under development. The BBC and other coverage both link the development to Oxford scientists and suggest the vaccine could be ready within months, though details about trial stages, timelines, and regulatory steps are not provided in the excerpts. The reporting focuses on the need for a targeted vaccine for this specific Ebola species rather than a general vaccine for all Ebola strains. Overall, the articles state that the project is in progress, that Bundibugyo has a high case-fatality rate, and that a ready-to-use vaccine is not yet available.